Table 1 Baseline characteristics of the study population in the CREDENCE derivation cohort
Variable | With primary endpoint (N = 187) | Without primary endpoint (N = 484) | P |
|---|---|---|---|
Age, years, mean (SD) | 61.9 (8.7) | 64.0 (8.8) | 0.006 |
Male sex, n (%) | 118/187 (63.1%) | 347/484 (71.7%) | 0.03 |
White race, n (%) | 121/187 (64.7%) | 353/484 (72.9%) | 0.04 |
Black race, n (%) | 12/187 (6.4%) | 34/484 (7%) | 0.87 |
eGFR, mL/min/1.73m2 mean (SD) | 49.4 (18.1) | 58.0 (17.7) | < 0.001 |
BMI, Kg/m2 mean (SD) | 30.8 (6.1) | 32.6 (6.4) | < 0.001 |
Systolic blood pressure, mmHg (SD) | 143.7 (16.3) | 139.8 (15.7) | 0.006 |
HbA1c, %, mean (SD) | 8.3 (1.3) | 8.0 (1.2) | 0.009 |
UACR mg/g, median (Q1, Q3) | 1867 (1070, 3003) | 740 (431, 1467) | 0.001 |
Duration of diabetes, years, mean (SD) | 15.7 (7.6) | 16 (8.5) | 0.67 |
History of heart failure, n (%) | 33/187 (17.6%) | 57/484 (11.8%) | 0.06 |
Diuretic use, n (%) | 92/187 (49.2%) | 249/484 (51.4%) | 0.61 |
NT-proBNP, ng/L, median (Q1, Q3) | 380 (163, 975) | 175 (81, 396) | 0.001 |
hs-cTnT, ng/L, median (Q1, Q3) | 27.8 (17.7, 42.9) | 18.5 (12.2, 26.7) | 0.001 |
IGFBP7, ng/mL, median (Q1, Q3) | 140.7 (123.4, 161.1) | 119.4 (104.4, 137.1) | < 0.001 |
GDF-15, ng/L, median (Q1, Q3) | 3269 (2340, 4929.5) | 2455.5 (1839.8, 3420.8) | < 0.001 |
IGFBP1, ng/mL, median (Q1, Q3) | 105 (72.6, 141.6) | 99.3 (75.8, 131.6) | 0.43 |
IGFBP3, ng/mL, median (Q1, Q3) | 3182 (2464, 4035) | 3085 (2430, 4003) | 0.59 |
sFLT-1, ng/mL, median (Q1, Q3) | 99.6 (88.3, 110.6) | 93 (85.6, 103.5) | < 0.001 |
VEGFA, pg/mL, median (Q1, Q3) | 64.5 (46, 114) | 61.6 (41, 100.1) | 0.19 |
Angiopoietin-2, ng/mL, median (Q1, Q3) | 2.2 (1.6, 3.1) | 1.8 (1.4, 2.5) | < 0.001 |
PlGF, ng/mL, median (Q1, Q3) | 19.0 (15.8, 21.9) | 16.5 (14, 19.5) | < 0.001 |